Vaxcyte, Inc. (PCVX)
61.16
+0.06
(+0.11%)
USD |
NASDAQ |
Aug 27, 16:00
61.18
+0.02
(+0.04%)
After-Hours: 20:00
Vaxcyte Enterprise Value : 7.483B for Aug. 27, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 27, 2026 | 7.483B |
| August 26, 2026 | 7.474B |
| August 25, 2026 | 7.474B |
| August 24, 2026 | 7.587B |
| August 21, 2026 | 7.695B |
| August 20, 2026 | 7.510B |
| August 19, 2026 | 7.794B |
| August 18, 2026 | 7.285B |
| August 17, 2026 | 7.348B |
| August 14, 2026 | 7.036B |
| August 13, 2026 | 7.151B |
| August 12, 2026 | 7.265B |
| August 11, 2026 | 7.203B |
| August 10, 2026 | 7.068B |
| August 07, 2026 | 7.036B |
| August 06, 2026 | 7.155B |
| August 05, 2026 | 6.725B |
| August 04, 2026 | 6.547B |
| August 03, 2026 | 6.379B |
| July 31, 2026 | 6.459B |
| July 30, 2026 | 6.731B |
| July 29, 2026 | 6.299B |
| July 28, 2026 | 6.534B |
| July 27, 2026 | 6.664B |
| July 24, 2026 | 6.543B |
| Date | Value |
|---|---|
| July 23, 2026 | 6.684B |
| July 22, 2026 | 6.737B |
| July 21, 2026 | 7.032B |
| July 20, 2026 | 6.664B |
| July 17, 2026 | 6.766B |
| July 16, 2026 | 6.742B |
| July 15, 2026 | 6.844B |
| July 14, 2026 | 6.767B |
| July 13, 2026 | 6.886B |
| July 10, 2026 | 7.057B |
| July 09, 2026 | 7.291B |
| July 08, 2026 | 7.129B |
| July 07, 2026 | 7.413B |
| July 06, 2026 | 6.876B |
| July 02, 2026 | 7.083B |
| July 01, 2026 | 6.748B |
| June 30, 2026 | 7.045B |
| June 29, 2026 | 6.709B |
| June 26, 2026 | 6.536B |
| June 25, 2026 | 6.126B |
| June 24, 2026 | 6.153B |
| June 23, 2026 | 5.878B |
| June 22, 2026 | 5.899B |
| June 18, 2026 | 5.803B |
| June 17, 2026 | 5.692B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Moderna, Inc. | 53.11B |
| Arrowhead Pharmaceuticals, Inc. | 12.28B |
| Oncolytics Biotech, Inc. | 102.27M |
| Sangamo Therapeutics, Inc. | 55.30M |
| Sarepta Therapeutics, Inc. | 2.538B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -284.30M |
| Total Expenses (Quarterly) | 284.30M |
| EPS Diluted (Quarterly) | -1.968 |
| Earnings Yield | -12.61% |
| Normalized Earnings Yield | -12.61 |